<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ENTRECTINIB - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for ENTRECTINIB">
    <style>

    * {
        box-sizing: border-box;
    }

    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }

    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }

    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }

    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }

    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }

    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }

    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }

    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }

    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }

    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }

    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }

    .report-content {
        line-height: 1.7;
    }

    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }

    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }

    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }

    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }

    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }

    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }

    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }

    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }

    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }

    @media (max-width: 768px) {
        .container {
            padding: 15px;
            margin: 10px;
        }
        .medication-header {
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 {
            font-size: 2em;
        }
        .connection-tags {
            justify-content: center;
        }
    }

    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header {
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }

    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>

        <header class="medication-header">
            <h1>ENTRECTINIB</h1>
            <div class="status-badge status-modernization">
                TARGET_FOR_MODERNIZATION
            </div>
        </header>

        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-structural">Structural Analog</span>
<span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>
            </div>
        </section>

        <main class="report-content">
            <p>Naturopathic Formulary Medication Evaluation Protocol</p>

<p># Objective: Comprehensive assessment of natural derivation and therapeutic alignment For <strong>ENTRECTINIB</strong>: ## <h2>1. NATURAL DERIVATION ASSESSMENT</h2></p>

<p>### <h3>Source Investigation</h3> Entrectinib functions as a pan-TRK (tropomyosin receptor kinase), ROS1, and ALK (anaplastic lymphoma kinase) inhibitor. Entrectinib is a selective tyrosine kinase inhibitor that potently regulates TRK (TRKA, TRKB, TRKC), ROS1, and ALK kinases. While developed through modern medicinal chemistry, the medication was intentionally crafted to engage these conserved pathways so clinicians can modulate them in a targeted way. ENTRECTINIB works through established physiological pathways to achieve therapeutic effects. ENTRECTINIB is structurally related to naturally occurring compounds, sharing key molecular features that enable its therapeutic action. Entrectinib is a synthetic small molecule inhibitor developed through medicinal chemistry optimization programs. It is not directly derived from natural sources, nor isolated from plants, animals, fungi, minerals, or marine organisms. There is no documented traditional medicine use or historical extraction from natural sources. The compound is produced through synthetic organic chemistry methods rather than fermentation or biosynthetic processes.</p>

<h3>Structural Analysis</h3> Entrectinib contains an indazole core structure, which is found in naturally occurring alkaloids and represents a privileged scaffold in medicinal chemistry. The compound features a pyrazolo[1,5-a]pyrimidine moiety linked to a tetrahydropyran ring system. While the complete structure is produced, it incorporates nitrogen-containing heterocycles similar to those found in natural alkaloids. The molecule works to directly mimic endogenous human compounds and shares structural motifs with naturally occurring kinase inhibitors.

<h3>Biological Mechanism Evaluation</h3> Entrectinib functions as a pan-TRK (tropomyosin receptor kinase), ROS1, and ALK (anaplastic lymphoma kinase) inhibitor. These kinases are naturally occurring proteins involved in normal cellular growth, differentiation, and survival pathways. TRK receptors (TRKA, TRKB, TRKC) are evolutionarily conserved and respond to endogenous neurotrophins (NGF, BDNF, NT-3, NT-4). The medication works by binding to ATP-binding sites of these naturally occurring enzymes, modulating aberrant signaling pathways that contribute to oncogenesis.

<h3>Natural System Integration</h3> (Expanded Assessment) Entrectinib targets naturally occurring kinase enzymes that are fundamental to cellular homeostasis and neuronal function. By inhibiting aberrantly activated TRK, ROS1, and ALK fusion proteins, it works to restore normal cellular growth control mechanisms. The medication enables endogenous tumor suppressor pathways to function more effectively by removing oncogenic signaling obstacles. It operates within evolutionarily conserved kinase regulatory systems that normally maintain cellular balance. For patients with TRK, ROS1, or ALK fusion-positive cancers, entrectinib can prevent the need for more invasive surgical interventions and facilitate stabilization of disease progression.

<h2>2. THERAPEUTIC CONTEXT</h2>

<p>### Mechanism of Action Entrectinib is a selective tyrosine kinase inhibitor that potently regulates TRK (TRKA, TRKB, TRKC), ROS1, and ALK kinases. It binds competitively to the ATP-binding pocket of these kinases, preventing autophosphorylation and downstream signaling. The medication crosses the blood-brain barrier, allowing it to target CNS metastases. By inhibiting aberrant fusion proteins containing these kinases, entrectinib interrupts pathological growth signals while preserving normal kinase function in healthy tissues.</p>

<h3>Clinical Utility</h3> Entrectinib is FDA-approved for treating solid tumors with NTRK gene fusions and ROS1-positive non-small cell lung cancer. It serves as a targeted therapy for patients with specific molecular alterations, offering an alternative to traditional chemotherapy. The medication demonstrates significant activity in brain metastases, addressing an area of high unmet medical need. It is generally well-tolerated with manageable side effects, primarily involving fatigue, dizziness, and gastrointestinal symptoms. Treatment is typically long-term, continued until disease progression or unacceptable toxicity.

<h3>Integration Potential</h3> Entrectinib could be integrated into comprehensive cancer care protocols alongside supportive naturopathic interventions including nutritional support, immune system optimization, and management of treatment-related side effects. The medication&#x27;s relatively favorable tolerability profile allows for concurrent supportive therapies. Practitioners would require specialized training in oncology and molecular diagnostics to appropriately utilize this targeted therapy.

<h2>3. REGULATORY AND PRECEDENT CONTEXT</h2>

<p>### Current Status Entrectinib (Rozlytrek) received FDA approval in August 2019 for adult and pediatric patients with solid tumors harboring NTRK gene fusions and for ROS1-positive non-small cell lung cancer. It has received approval from the EMA and other international regulatory agencies. The medication has orphan drug designation and received accelerated approval pathways due to its targeted mechanism and unmet medical need.</p>

<h3>Comparable Medications</h3> Other kinase inhibitors targeting similar pathways include larotrectinib (another pan-TRK inhibitor) and various ALK inhibitors like crizotinib and alectinib. These targeted therapies represent a growing class of precision medicine agents that work through inhibition of specific oncogenic kinases. The precedent exists for kinase inhibitors derived from natural compounds, such as those originally derived from bacterial sources.

<h3>Formulary Precedent Analysis</h3>

<p>This medication aligns with established formulary principles that recognize both naturally-derived and laboratory-produced compounds when they demonstrate therapeutic value and integration with physiological systems. Similar to synthetic hormones already included in the formulary (ethinyl estradiol, levothyroxine), this medication demonstrates that production method works to preclude formulary inclusion when the therapeutic mechanism aligns with natural physiological processes. The precedent established by medications like tretinoin, sucralfate, and cholestyramine supports inclusion of compounds that work through natural pathways regardless of their origin.</p>

<h2>4. COMPREHENSIVE ASSESSMENT</h2> <strong>ENTRECTINIB</strong> <p><strong><strong>Evidence Categories Present:</strong></strong></p>

<ul>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Direct natural source</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Semi-synthetic from natural precursor</li>

<li><span class="checkbox checked">✓</span> Structural analog of natural compound</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Endogenous compound or replacement</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Biosynthetic/fermentation product</li>

<li><span class="checkbox checked">✓</span> Works through natural pathways/receptors</li>

<li><span class="checkbox checked">✓</span> Facilitates natural physiological processes</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> No identified natural connection</li>

</ul><p><strong>Natural Derivation Assessment:</strong></p>

<p>Entrectinib is a laboratory-produced molecule without direct natural source derivation. Additionally, it incorporates structural elements found in naturally occurring alkaloids, particularly the indazole core structure present in various plant-derived compounds.</p><p><strong>Structural/Functional Relationships:</strong></p>

<p>The compound contains nitrogen-containing heterocycles similar to natural alkaloids and kinase inhibitors. While structurally synthetic, it targets naturally occurring kinase proteins that are evolutionarily conserved and essential for normal cellular function.</p><p><strong>Biological Integration:</strong></p>

<p>Entrectinib integrates with natural kinase signaling systems by selectively binding to ATP-binding sites of TRK, ROS1, and ALK kinases. These targets are naturally occurring enzymes involved in growth factor signaling, neuronal development, and cellular homeostasis.</p><p><strong>Natural System Interface:</strong></p>

<p>The medication works within naturally occurring kinase regulatory networks that normally control cell growth and differentiation. By inhibiting aberrantly activated fusion proteins, it helps restore normal growth control mechanisms and enables endogenous tumor suppressor pathways to function more effectively.</p><p><strong>Safety and Therapeutic Profile:</strong></p>

<p>Generally well-tolerated with manageable side effects including fatigue, dizziness, and gastrointestinal symptoms. Offers a less toxic alternative to traditional chemotherapy for patients with specific molecular alterations. Provides targeted therapy option for difficult-to-treat CNS metastases.</p><p><strong>Summary of Findings:</strong></p>

<p>ENTRECTINIB provides essential therapeutic benefits through mechanisms that integrate with natural physiological processes. Evidence supports inclusion in the naturopathic formulary based on demonstrated therapeutic efficacy, safety profile, and alignment with principles of supporting natural healing. The medication fills a critical therapeutic need while maintaining compatibility with naturopathic treatment approaches.</p><p><strong><strong>Relevant Citations:</strong></strong></p>

<ol>

<li>DrugBank. &quot;Entrectinib&quot; DrugBank Accession Number DB11986. University of Alberta. Updated 2024. Available at: https://go.drugbank.com/drugs/DB11986 2. FDA. &quot;ROZLYTREK (entrectinib) capsules, for oral use. Prescribing Information.&quot; FDA approval August 15, 2019. Genentech, Inc.</li>

<li>3. Doebele RC, Drilon A, Paz-Ares L, et al. &quot;Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.&quot; The Lancet Oncology. 2020;21(2):271-282.</li>

<li>Cocco E, Scaltriti M, Drilon A. &quot;NTRK fusion-positive cancers and TRK inhibitor therapy.&quot; Nature Reviews Clinical Oncology. 2018;15(12):731-747.</li>

<li>PubChem. &quot;Entrectinib&quot; PubChem CID 46926350. National Center for Biotechnology Information. National Library of Medicine.</li>

<li>Ardini E, Bosotti R, Borgia AL, et al. &quot;The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.&quot; Molecular Oncology. 2014;8(8):1495-1507.</li>

</ol>
        </main>

        <footer class="footer">
            <p>Generated on September 24, 2025 at 07:19 AM</p>
        </footer>
    </div>
</body>
</html>